查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030年全球動脈粥樣硬化藥物市場規模研究與預測，按階段、按診斷、按治療、按給藥途徑、按終端用戶、按配銷通路和區域分析。
市場調查報告書
商品編碼
1290509

2023-2030年全球動脈粥樣硬化藥物市場規模研究與預測，按階段、按診斷、按治療、按給藥途徑、按終端用戶、按配銷通路和區域分析。

Global Atherosclerosis drugs Market Size study & Forecast, by Stages, by Diagnosis, by Treatment, by Route of Administration, by End-Users, by Distribution Channel and Regional Analysis, 2023-2030
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

2022年全球動脈粥樣硬化藥物市場價值約為27億美元，預計在2023-2030年的預測期內將以超過6.16%的健康成長率成長。動脈粥樣硬化藥物是用於治療動脈粥樣硬化和相關心血管疾病（如心臟病發作、中風和外周血管疾病）的一類治療藥物。這種市場成長歸因於患者大量消費降膽固醇藥物以減少或避免動脈阻塞。越來越快節奏的生活方式使普通人平時的飲食中的基本營養素消耗殆盡，增加了動脈粥樣硬化的風險，儘管年齡組和動脈粥樣硬化市場的成長率是醫療支出的上升，這有助於改善其基礎設施。醫療保健部門的研究和開發促使了全球有效的動脈粥樣硬化藥物的生產。

據預測，動脈粥樣硬化的風險增加，肥胖和高膽固醇的流行率增加，將促進市場的成長率。根據世界衛生組織（WHO）2020年的估計，有4000萬五歲以下的兒童超重或肥胖。高脂肪和高糖食物消費的增加，以及許多工作對體力要求的降低所帶來的身體不移動的增加，交通方式的改變和城市化的發展，都是促使人們膽固醇高的因素，推動了市場的快速擴張。此外，研究和開發活動數量的增加也推動了市場的成長，電子商務和醫療保健部門的整合將通過網上藥店為動脈粥樣硬化藥物市場的公司帶來可觀的銷售潛力。然而，藥物的副作用和非專利產品的可用性是預計在預測期間限制市場成長的因素。

全球動脈粥樣硬化藥物市場研究涵蓋的主要地區包括亞太、北美、歐洲、拉美和中東及非洲。北美在2022年主導市場，佔有最大的市場佔有率，因為該地區動脈粥樣硬化的頻率增加和治療的技術改進。此外，醫療支出的增加和重要的關鍵參與者的存在將推動該地區的市場發展速度。根據2022年7月更新的國家慢性病預防和健康促進中心的心臟病和中風預防部門，在美國每34秒就有一人死於心血管疾病。在預測期內，亞太地區預計將大幅成長，因為該地區的老年人口不斷增加，可支配收入水平不斷提高。此外，醫療部門基礎設施的擴張和政府的不斷努力將加速該地區的市場擴張。

本報告中包括的主要市場參與者有

  • F.Hoffmann-La Roche Ltd.
  • Mylan NV
  • 梯瓦製藥工業有限公司
  • Sanofi SA
  • 輝瑞公司
  • GlaxoSmithKline plc
  • 諾華製藥公司
  • 默克公司
  • 艾爾建公司（Allergan Plc
  • 阿斯利康

市場的最新發展：

  • 2022年9月，諾和諾德與微軟達成了新的戰略合作，通過使用巨量資料和人工智慧（AI）加速藥物研發。該團隊將採用人工智慧來構建模型，以預測一個人獲得動脈粥樣硬化或動脈斑塊發展的風險。研究人員還將尋找新的動脈硬化目標和指標。
  • 2022年8月，阿斯利康和默克（在美國和加拿大以外稱為MSD）宣布，歐盟委員會（EC）已批准LYNPARZA作為單一療法或與內分泌療法聯合，用於輔助治療曾接受新輔助或輔助化療的種系BRCA1/2突變（gBRCAm）和HER2陰性高風險早期乳腺癌的成年患者。

全球動脈硬化藥物市場報告範圍：

  • 歷史數據： 2020 - 2021
  • 估計的基準年： 2022年
  • 預測期： 2023-2030年
  • 報告涵蓋範圍：收入預測，公司排名，競爭格局，成長因素，和趨勢
  • 涵蓋的細分市場：分期、診斷、治療、給藥途徑、終端用戶、配銷通路、地區
  • 區域範圍：北美洲；歐洲；亞太地區；拉丁美洲；中東和非洲
  • 定製範圍：購買後可免費定製報告（相當於8個分析員的工作時間）。增加或改變國家、區域和部門範圍*。
  • 本研究的目的是確定近年來不同細分市場和國家的市場規模，並對未來幾年的價值進行預測。該報告旨在將研究涉及的國家內的行業的品質和數量方面都涵蓋其中。

該報告還提供了關於關鍵方面的詳細資訊，如驅動因素和挑戰，這將確定市場的未來成長。此外，它還涵蓋了微觀市場的潛在機會，供利益相關者投資，並詳細分析了競爭格局和主要參與者的產品。 .

目錄

第一章：執行摘要

  • 市場簡介
  • 2020-2030年全球和細分市場的估計和預測
    • 2020-2030年，動脈粥樣硬化藥物市場，按地區分類
    • 動脈粥樣硬化藥物市場，按階段分類，2020-2030年
    • 2020-2030年，動脈粥樣硬化藥物市場，按診斷方法分類
    • 2020-2030年，動脈粥樣硬化藥物市場，按治療方法分類
    • 2020-2030年，動脈粥樣硬化藥物市場，按給藥途徑分類
    • 2020-2030年，動脈粥樣硬化藥物市場，按終端用戶分類
    • 2020-2030年動脈粥樣硬化藥物市場，按配銷通路分類
  • 主要趨勢
  • 估算方法
  • 研究假設

第二章：全球動脈粥樣硬化藥物市場的定義和範圍

  • 本研究的目的
  • 市場定義和範圍
    • 行業演變
    • 研究的範圍
  • 研究涵蓋的年份
  • 貨幣轉換率

第三章：全球動脈粥樣硬化藥物市場動態

  • 動脈硬化藥物市場影響分析（2020-2030年）
    • 市場驅動力
      • 對醫療基礎設施的投資不斷增加
      • 不斷成長的老年人口
    • 市場挑戰
      • 成本高，診斷率低
      • 藥物的副作用
    • 市場機會
      • 研究和開發活動的數量增加
      • 政府計劃對提高醫療服務和基礎設施的標準至關重要

第四章：全球動脈粥樣硬化藥物市場：行業分析

  • 波特的五力模型
    • 供應商的議價能力
    • 買方的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭性的競爭
  • 波特五力影響分析
  • PEST分析
    • 政治
    • 經濟
    • 社會
    • 技術
    • 環境
    • 法律
  • 最佳投資機會
  • 最佳策略
  • COVID-19影響分析
  • 顛覆性趨勢
  • 行業專家的觀點
  • 分析師建議與結論

第五章：全球動脈硬化藥物市場，按階段分類

  • 市場簡介
  • 全球動脈粥樣硬化藥物市場，按階段、性能-潛力分析
  • 2020-2030年全球動脈粥樣硬化藥物市場按階段的估計和預測
  • 動脈粥樣硬化藥物市場，細項分析
    • 內皮損傷和免疫反應
    • 脂肪條紋
    • 斑塊生長
    • 斑塊破裂

第六章：全球動脈粥樣硬化藥物市場，按診斷分類

  • 市場簡介
  • 全球動脈粥樣硬化藥物市場，按診斷，性能- 潛力分析
  • 2020-2030年全球動脈粥樣硬化藥物市場按診斷的估計和預測
  • 動脈粥樣硬化藥物市場，次級細項分析
    • 踝臂指數
    • 多普勒超聲檢查
    • 超聲心動圖
    • 心電圖
    • 血液檢查
    • 其他檢查

第7章：全球動脈粥樣硬化藥物市場，按治療方法分類

  • 市場簡介
  • 全球動脈粥樣硬化藥物市場，按治療方法，性能-潛力分析
  • 2020-2030年全球動脈粥樣硬化藥物市場按治療方法估計和預測的情況
  • 動脈粥樣硬化症藥物市場，細項分析
    • 藥物治療
    • 手術治療
    • 其他療法

第八章：全球動脈粥樣硬化藥物市場，按給藥途徑分類

  • 市場簡介
  • 按給藥途徑分類的全球動脈粥樣硬化藥物市場，表現- 潛力分析
  • 2020-2030年全球動脈粥樣硬化藥物市場按給藥途徑估計和預測的情況
  • 動脈粥樣硬化症藥物市場，細項分析
    • 口服
    • 腸外
    • 其他途徑

第九章：全球動脈粥樣硬化藥物市場，按終端用戶分類

  • 市場簡介
  • 按終端用戶分類的全球動脈粥樣硬化藥物市場，性能-潛力分析
  • 2020-2030年全球動脈粥樣硬化藥物市場按終端用戶的估計和預測
  • 動脈粥樣硬化症藥物市場，細項分析
    • 醫院
    • 專業診所
    • 家庭護理
    • 其他

第十章：全球動脈粥樣硬化藥物市場，按配銷通路分類

  • 市場簡介
  • 按配銷通路分類的全球動脈粥樣硬化藥物市場，表現- 潛力分析
  • 2020-2030年全球動脈粥樣硬化藥物市場按配銷通路的估計和預測
  • 動脈粥樣硬化症藥物市場，細項分析
    • 醫院藥房
    • 零售藥店
    • 網上藥店
    • 其他管道

第十一章：全球動脈硬化藥物市場，區域分析

  • 最領先的國家
  • 新興國家
  • 動脈粥樣硬化症藥物市場，區域市場簡介
  • 北美洲
    • 美國
      • 2020-2030年各階段細分估計和預測
      • 2020-2030年，診斷的細分估計和預測
      • 2020-2030年，治療細分的估計和預測
      • 2020-2030年給藥途徑細分的估計和預測
      • 2020-2030年終端用戶分類估計和預測
      • 2020-2030年配銷通路細分的估計和預測
    • 加拿大
  • 歐洲動脈粥樣硬化藥物市場簡介
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區動脈粥樣硬化藥物市場簡介
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 亞太其他地區
  • 拉丁美洲動脈粥樣硬化藥物市場簡介
    • 巴西
    • 墨西哥
  • 中東和非洲
    • 沙烏地
    • 南非
    • 中東和非洲其他地區

第十二章：競爭情報

  • 主要公司SWOT分析
    • 公司1
    • 公司二
    • 公司3
  • 頂級市場戰略
  • 公司簡介
    • F. Hoffmann-La Roche Ltd.
      • 關鍵資訊
      • 概況
      • 財務（取決於數據的可用性）
      • 產品摘要
      • 近期發展情況
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi India
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Novartis AG
    • Merck & Co
    • Allergan India Pvt Ltd.
    • AstraZeneca

第十三章：研究過程

  • 研究過程
    • 資料探勘
    • 分析
    • 市場評估
    • 驗證
    • 出版
  • 研究屬性
  • 研究假設

Global Atherosclerosis drugs Market is valued approximately at USD 2.7 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.16% over the forecast period 2023-2030. Atherosclerosis drugs is a therapeutic category of medications used for the treatment of atherosclerosis and related cardiovascular diseases such as heart attacks, strokes, and peripheral vascular disease. This market growth is attributed to the high consumption of cholesterol-lowering drugs by patients to reduce or avoid blockages in arteries. The increasingly fast-paced lifestyle has depleted the ordinary person's usual diet of essential nutrients that increases the risk of atherosclerosis, despite the age group and the growth rate of atherosclerosis market is the rising healthcare expenditure which helps in improving its infrastructure. The research and development in the healthcare sector have led to the production of effective atherosclerosis drugs globally.

Increasing the risk of atherosclerosis, the increased prevalence of obesity and high cholesterol is predicted to boost the market's growth rate. According to estimates from the World Health Organisation (WHO) in 2020, 40 million children under the age of five were overweight or obese. Increased consumption of food high in fat and sugar as well as an increase in physical immobility brought on by the fact that many jobs are becoming less physically demanding, changing transportation options and growing urbanization are the factors that contributes to high cholesterol rates in people that are driving the market's rapid expansion. Moreover, the market's growth is fueled by an increase in the number of research and development activities also the integration of e-Commerce and the healthcare sector will generate considerable sales potential through online pharmacies for companies in the atherosclerosis medicines market. However, Side effects of drugs and the availability of generic products are the factors expected to restrain the market growth during the forecast period.

The key regions considered for the Global Atherosclerosis drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 holding the largest market share owing to the increased frequency of atherosclerosis and technical improvement in the treatment in this region. Furthermore, increased healthcare expenditure and the presence of significant key players would drive the market development rate in this area. According to the National Centre for Chronic Disease Prevention and Health Promotion's Division for Heart Disease and Stroke Prevention, which was updated in July 2022, one person dies from cardiovascular disease every 34 seconds in the United States. Asia Pacific is expected to grow significantly during the forecast period, owing to the growing elderly population in this area and the rising level of disposable income. Additionally, the expansion of the healthcare sector's infrastructure and growing government efforts will accelerate the market's expansion in this area.

Major market player included in this report are:

  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Merck & Co
  • Allergan Plc
  • AstraZeneca

Recent Developments in the Market:

  • In September 2022, Novo Nordisk has entered into a new strategic cooperation with Microsoft to accelerate medication research and development via the use of big data and artificial intelligence (AI). The team will employ artificial intelligence to construct models that can predict a person's risk of getting atherosclerosis or arterial plaque development. The researchers will also look for new atherosclerosis targets and indicators.
  • In August 2022, AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the European Commission (EC) has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) and HER2-negative high-risk early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy.

Global Atherosclerosis drugs Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Stages, Diagnosis, Treatment, Route of Administration, End-Users, Distribution Channel, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
  • The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Stages:

  • Endothelial Damage and Immune Response
  • Fatty Streak
  • Plaque Growth
  • Plaque Rupture

By Diagnosis:

  • Ankle-brachial Index
  • Doppler Ultrasound
  • Echocardiogram
  • Electrocardiogram
  • Blood Tests
  • Others

By Treatment:

  • Medication
  • Surgery
  • Others

By Route of Administration:

  • Oral,
  • Parenteral
  • Others

By End-Users:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Atherosclerosis drugs Market, by region, 2020-2030 (USD Billion)
    • 1.2.2. Atherosclerosis drugs Market, by Stages, 2020-2030 (USD Billion)
    • 1.2.3. Atherosclerosis drugs Market, by Diagnosis, 2020-2030 (USD Billion)
    • 1.2.4. Atherosclerosis drugs Market, by Treatment, 2020-2030 (USD Billion)
    • 1.2.5. Atherosclerosis drugs Market, by Route of Administration, 2020-2030 (USD Billion)
    • 1.2.6. Atherosclerosis drugs Market, by End-User, 2020-2030 (USD Billion)
    • 1.2.7. Atherosclerosis drugs Market, by Distribution Channel, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Atherosclerosis drugs Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Atherosclerosis drugs Market Dynamics

  • 3.1. Atherosclerosis drugs Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing investment in healthcare infrastructure
      • 3.1.1.2. Growing Geriatric Population
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost and low diagnostic rates
      • 3.1.2.2. Side effects of drugs
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increase in the number of research and development activities
      • 3.1.3.2. Government initiatives have been essential in raising the standard of healthcare services and infrastructure

Chapter 4. Global Atherosclerosis drugs Market: Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economic
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Atherosclerosis drugs Market, by Stages

  • 5.1. Market Snapshot
  • 5.2. Global Atherosclerosis drugs Market by Stages, Performance - Potential Analysis
  • 5.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Stages 2020-2030 (USD Billion)
  • 5.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 5.4.1. Endothelial Damage and Immune Response
    • 5.4.2. Fatty Streak
    • 5.4.3. Plaque Growth
    • 5.4.4. Plaque Rupture

Chapter 6. Global Atherosclerosis drugs Market, by Diagnosis

  • 6.1. Market Snapshot
  • 6.2. Global Atherosclerosis drugs Market by Diagnosis, Performance - Potential Analysis
  • 6.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Diagnosis 2020-2030 (USD Billion)
  • 6.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 6.4.1. Ankle-brachial Index
    • 6.4.2. Doppler Ultrasound
    • 6.4.3. Echocardiogram
    • 6.4.4. Electrocardiogram
    • 6.4.5. Blood Tests
    • 6.4.6. Others

Chapter 7. Global Atherosclerosis drugs Market, by Treatment

  • 7.1. Market Snapshot
  • 7.2. Global Atherosclerosis drugs Market by Treatment, Performance - Potential Analysis
  • 7.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Treatment 2020-2030 (USD Billion)
  • 7.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 7.4.1. Medication
    • 7.4.2. Surgery
    • 7.4.3. Others

Chapter 8. Global Atherosclerosis drugs Market, by Route of Administration

  • 8.1. Market Snapshot
  • 8.2. Global Atherosclerosis drugs Market by Route of Administration, Performance - Potential Analysis
  • 8.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
  • 8.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 8.4.1. Oral
    • 8.4.2. Parenteral
    • 8.4.3. Others

Chapter 9. Global Atherosclerosis drugs Market, by End-User

  • 9.1. Market Snapshot
  • 9.2. Global Atherosclerosis drugs Market by End-User, Performance - Potential Analysis
  • 9.3. Global Atherosclerosis drugs Market Estimates & Forecasts by End-User2020-2030 (USD Billion)
  • 9.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 9.4.1. Hospitals
    • 9.4.2. Specialty Clinics
    • 9.4.3. Homecare
    • 9.4.4. Others

Chapter 10. Global Atherosclerosis drugs Market, by Distribution Channel

  • 10.1. Market Snapshot
  • 10.2. Global Atherosclerosis drugs Market by Distribution Channel, Performance - Potential Analysis
  • 10.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
  • 10.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Online Pharmacy
    • 10.4.4. Others

Chapter 11. Global Atherosclerosis drugs Market, Regional Analysis

  • 11.1. Top Leading Countries
  • 11.2. Top Emerging Countries
  • 11.3. Atherosclerosis drugs Market, Regional Market Snapshot
  • 11.4. North America Atherosclerosis Drugs Market
    • 11.4.1. U.S. Atherosclerosis drugs Market
      • 11.4.1.1. Stages breakdown estimates & forecasts, 2020-2030
      • 11.4.1.2. Diagnosis breakdown estimates & forecasts, 2020-2030
      • 11.4.1.3. Treatment breakdown estimates & forecasts, 2020-2030
      • 11.4.1.4. Route of Administration breakdown estimates & forecasts, 2020-2030
      • 11.4.1.5. End-User breakdown estimates & forecasts, 2020-2030
      • 11.4.1.6. Distribution Channel breakdown estimates & forecasts, 2020-2030
    • 11.4.2. Canada Atherosclerosis drugs Market
  • 11.5. Europe Atherosclerosis drugs Market Snapshot
    • 11.5.1. U.K. Atherosclerosis drugs Market
    • 11.5.2. Germany Atherosclerosis drugs Market
    • 11.5.3. France Atherosclerosis drugs Market
    • 11.5.4. Spain Atherosclerosis drugs Market
    • 11.5.5. Italy Atherosclerosis drugs Market
    • 11.5.6. Rest of Europe Atherosclerosis drugs Market
  • 11.6. Asia-Pacific Atherosclerosis drugs Market Snapshot
    • 11.6.1. China Atherosclerosis drugs Market
    • 11.6.2. India Atherosclerosis drugs Market
    • 11.6.3. Japan Atherosclerosis drugs Market
    • 11.6.4. Australia Atherosclerosis drugs Market
    • 11.6.5. South Korea Atherosclerosis drugs Market
    • 11.6.6. Rest of Asia Pacific Atherosclerosis Drugs Market
  • 11.7. Latin America Atherosclerosis drugs Market Snapshot
    • 11.7.1. Brazil Atherosclerosis drugs Market
    • 11.7.2. Mexico Atherosclerosis drugs Market
  • 11.8. Middle East & Africa Atherosclerosis drugs Market
    • 11.8.1. Saudi Arabia Atherosclerosis drugs Market
    • 11.8.2. South Africa Atherosclerosis drugs Market
    • 11.8.3. Rest of Middle East & Africa Atherosclerosis drugs Market

Chapter 12. Competitive Intelligence

  • 12.1. Key Company SWOT Analysis
    • 12.1.1. Company 1
    • 12.1.2. Company 2
    • 12.1.3. Company 3
  • 12.2. Top Market Strategies
  • 12.3. Company Profiles
    • 12.3.1. F. Hoffmann-La Roche Ltd.
      • 12.3.1.1. Key Information
      • 12.3.1.2. Overview
      • 12.3.1.3. Financial (Subject to Data Availability)
      • 12.3.1.4. Product Summary
      • 12.3.1.5. Recent Developments
    • 12.3.2. Mylan N.V.
    • 12.3.3. Teva Pharmaceutical Industries Ltd.
    • 12.3.4. Sanofi India
    • 12.3.5. Pfizer Inc.
    • 12.3.6. GlaxoSmithKline plc
    • 12.3.7. Novartis AG
    • 12.3.8. Merck & Co
    • 12.3.9. Allergan India Pvt Ltd.
    • 12.3.10. AstraZeneca

Chapter 13. Research Process

  • 13.1. Research Process
    • 13.1.1. Data Mining
    • 13.1.2. Analysis
    • 13.1.3. Market Estimation
    • 13.1.4. Validation
    • 13.1.5. Publishing
  • 13.2. Research Attributes
  • 13.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Atherosclerosis drugs Market, report scope
  • TABLE 2. Global Atherosclerosis drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Atherosclerosis drugs Market estimates & forecasts by Stages 2020-2030 (USD Billion)
  • TABLE 4. Global Atherosclerosis drugs Market estimates & forecasts by Diagnosis 2020-2030 (USD Billion)
  • TABLE 5. Global Atherosclerosis drugs Market estimates & forecasts by Treatment 2020-2030 (USD Billion)
  • TABLE 6. Global Atherosclerosis drugs Market estimates & forecasts by Route of Administration 2020-2030 (USD Billion)
  • TABLE 7. Global Atherosclerosis drugs Market estimates & forecasts by End-User 2020-2030 (USD Billion)
  • TABLE 8. Global Atherosclerosis drugs Market estimates & forecasts by Distribution Channel 2020-2030 (USD Billion)
  • TABLE 9. Global Atherosclerosis drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Atherosclerosis drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Atherosclerosis drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Atherosclerosis drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Atherosclerosis drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Atherosclerosis drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. Global Atherosclerosis drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. Global Atherosclerosis drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17. Global Atherosclerosis drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 18. Global Atherosclerosis drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 19. U.S. Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 20. U.S. Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. U.S. Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. Canada Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 23. Canada Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. Canada Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. UK Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 26. UK Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. UK Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. Germany Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 29. Germany Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. Germany Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. France Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 32. France Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. France Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Italy Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 35. Italy Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. Italy Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. Spain Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 38. Spain Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. Spain Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. RoE Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 41. RoE Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. RoE Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. China Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 44. China Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. China Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. India Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 47. India Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. India Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. Japan Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 50. Japan Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. Japan Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. South Korea Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 53. South Korea Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. South Korea Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. Australia Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 56. Australia Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. Australia Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. RoAPAC Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 59. RoAPAC Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. RoAPAC Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Brazil Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 62. Brazil Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. Brazil Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. Mexico Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 65. Mexico Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. Mexico Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. RoLA Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 68. RoLA Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. RoLA Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70. Saudi Arabia Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 71. South Africa Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 72. RoMEA Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 73. List of secondary sources, used in the study of global Atherosclerosis drugs Market
  • TABLE 74. List of primary sources, used in the study of global Atherosclerosis drugs Market
  • TABLE 75. Years considered for the study
  • TABLE 76. Exchange rates considered

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Atherosclerosis drugs Market, research methodology
  • FIG 2. Global Atherosclerosis drugs Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Atherosclerosis drugs Market, key trends 2022
  • FIG 5. Global Atherosclerosis drugs Market, growth prospects 2023-2030
  • FIG 6. Global Atherosclerosis drugs Market, porters 5 force model
  • FIG 7. Global Atherosclerosis drugs Market, pest analysis
  • FIG 8. Global Atherosclerosis drugs Market, value chain analysis
  • FIG 9. Global Atherosclerosis drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Atherosclerosis drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Atherosclerosis drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Atherosclerosis drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Atherosclerosis drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Atherosclerosis drugs Market, regional snapshot 2020 & 2030
  • FIG 15. North America Atherosclerosis drugs Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Atherosclerosis drugs Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Atherosclerosis drugs Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Atherosclerosis drugs Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Atherosclerosis drugs Market 2020 & 2030 (USD Billion)

List of tables and figures are dummy in nature, final lists may vary in the final deliverable